Johns Hopkins: The #1 Coronavirus Vaccine

coronavirus vaccine

One of America’s top medical universities says . . .

Just one vaccine could cure the Covid-19 outbreak.

Get urgent details on the #1 biotech for 3,825% profits.

Peter Thielen is a molecular geneticist at Johns Hopkins University.

He reports that there are only 4 – 10 genetic differences between the various strains of Covid-19. And he says . . .

“That’s a relatively small number of mutations for having passed through a large number of people. At this point the mutation rate of the virus would suggest that the vaccine developed for SARS-CoV-2 would be a single vaccine.”

That means that one vaccine could be used to treat all coronavirus patients (click here for details on the company “fast tracked” by the FDA).

That’s different than the seasonal flu. Each year, a new vaccine is created to prevent the flu. And it changes every year because the flu virus mutates.

The Covid-19 vaccine would be more similar to those used for chickenpox and measles. So, a single vaccine can protect patients over the long term.

This is a huge development . . .

And it shows that the first company to develop the Covid-19 vaccine will reap remarkable profits.

My initial estimates suggested that this market could be worth $15.6 billion in the U.S.

Globally a coronavirus vaccine could generate sales topping $156 billion!

Yet my estimates were based upon only 25% of the world’s adult population receiving the immunization.

If the Covid-19 vaccine is preventative – like chickenpox or measles – the numbers would surge. For example, 86% of the world’s population is vaccinated against measles. So, the coronavirus vaccine could see similar mass adoption.

Right now, America’s best biotech companies are rushing to begin clinical trials. And thousands of patients are being enrolled in trials at hospitals around the world.

Experts say that the typical new vaccine takes 12 – 18 months to develop and test. Yet the mad rush to cure coronavirus means this could be greatly accelerated.

So, you could be looking at a vaccine being available on a much faster timeline of just 6 – 12 months.

The biotech stock to create this new vaccine will see windfall profits. And my research suggests that this tiny biotech could surge 3,825% within the next year.

That’s enough to turn a small $2k investment into over $78,503!

Get all the details inside today’s urgent briefing.

Just click here – it’s FREE.

Yours in Health & Wealth,
Ian Wyatt

To top